Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6800+0.2900 (+12.13%)
At close: 04:00PM EDT
2.6908 +0.01 (+0.40%)
After hours: 07:50PM EDT
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
87
95
156
114,089
0
-
Operating expenses
Research development
214,935
242,914
256,387
220,176
192,987
-
Selling general and administrative
70,056
71,673
79,305
74,105
65,256
-
Total operating expenses
284,991
314,587
335,692
294,281
258,243
-
Operating income or loss
-284,904
-314,492
-335,536
-180,192
-258,243
-
Interest expense
-
-
-
-
0
0
Total other income/expenses net
-29,074
-31,080
-9,444
-3,573
-67,302
-
Income before tax
-292,297
-327,265
-340,414
-182,051
-316,381
-
Income tax expense
-
-
-
0
0
-331
Income from continuing operations
-292,297
-327,265
-340,414
-182,051
-316,381
-
Net income
-292,297
-327,265
-340,414
-182,051
-316,381
-
Net income available to common shareholders
-292,297
-327,265
-340,414
-182,051
-316,381
-
Basic EPS
-2.20
-2.09
-2.38
-1.34
-2.63
-
Diluted EPS
-2.20
-2.09
-2.38
-1.34
-2.63
-
Basic average shares
150,856
156,932
143,147
135,820
120,370
-
Diluted average shares
150,856
156,932
143,147
135,820
120,370
-